It is estimated that 30% of perishable food crops are lost in transit, costing billions of dollars in profits and putting additional pressure on already high food costs. With biofuels diverting crops formerly grown for food, such unnecessary losses are now driving the problem into the realm of national security.
This new publication will cover such technologies as insulating materials and containers, phase-change materials, smart labels and sensors, desiccants, returnable notes and pallets, tamper-evident cases, specialty logistics services, and more.
Gives Doctors Insight into Patient's Medication Habits, Monitors Critical Drugs with Addictive Potential
Extended-release opiates are state-of-the-art medications for managing moderate to severe chronic pain. They are safe when used as directed, but they do have high potential for abuse and addiction.
Risk Management System for Schedule II Controlled Substances: "Careful monitoring of the patient’s compliance early in treatment before the dependence cycle begins may allow the therapist to guide the patient in responsible, non-problematic use of opiate analgesics."
Patient Compliance (Adherence) and Persistence with Prescribed Medication: "Until the newest generation of ECMs became available, little could be done to assess the degree to which side effects or poor clinical response are due to poor compliance, other than asking the patient if he or she was taking their medication as directed (with notoriously unreliable responses)."
Power and Return on Investment in Clinical Research: At some point, perhaps not in the far future,it will seem as wrong to run a clinical trial without compliance measurement as without randomization. --B. Efron, Statistics in Medicine, 1998 (17), 249-250.
Pharmacy as a Signal to Noise Ratio: Pharmacotherapy may be viewed in terms of a signal to noise ratio (S/N). In administering any medication, the aim is to maximize the S/N. The signal is the desired clinical effect; the noise comprises a multitude of factors that interfere with, or obscure, the clinical effect ...
How much does your compliance data cost? Clinical trial costs are spiraling out of control. Recently completed studies have pegged the cost of bringing a new drug to market at from 500 to 800 million dollars. Data handling and pickup costs related to patient records account for a staggering 30 percent of drug development costs. Dig deeper into the issues Information Mediary Corp.has addressed in past reports and discover some further numbers on the cost of tracking noncompliance in clinical trials settings.
Do Your Patients Report Accurately? The problem of clinical trials involving patient-determined dosing is widely recognized. If data obtained in clinical trials where patients take medication once or twice a day are known to be inaccurate, it follows that data from patients taking medication intermittently over longer intervals will be even less accurate.
How valid are your clinical trials data? It is widely accepted that patients participating in clinical trials are less than perfectly compliant with their medication regimens. The extent to which noncompliance affects the results of clinical trials is unknown. Several factors mitigate against the assessment of this phenomenon, principal of which is the lack of a methodology to monitor patient compliance in a noninvasive way.
